GFAP and Alzheimer disease: Both CSF biomarker levels allowed a good distinction between AD vs. HC and MCI vs. AD (NfL p < 0.001 for both measurements, GFAP p < 0.05 and p < 0.01, respectively), while a significant differentiation between HC vs. MCI could not be demonstrated.